1 e frontal and temporal cortex from 15 AD,
15 VaD and 15 control brains.
2 9; 95% confidence interval [CI], 1.35-1.
43),
VaD (1.66; 1.61-1.72), and all-cause dementia (1.57; 1.5
3 date key intercellular pathways, we employ
a VaD mouse model with focal ischemia replicating many ele
4 ns with glaucoma had increased risks for
AD,
VaD, and all-cause dementia, particularly those diagnose
5 uroimaging phenotypes associated with AD
and VaD (separately) in a cohort of nondemented, nondepresse
6 When we examined AD
and VaD separately, subjects with late-life depressive sympt
7 ntribute to vascular abnormalities in AD
and VaD.
8 ive health conditions associated with AD
and VaD.
9 All-cause dementia, AD,
and VaD, classified by a multidisciplinary committee using s
10 Chronic cerebral hypoperfusion
and VaD was induced by bilateral common carotid artery occlu
11 uences of chronic cerebral hypoperfusion
and VaD.
12 ith AD [i.e., learning and memory (L&M)]
and VaD (i.e., information processing and executive function
13 1.36; and 1.28; 1.20-1.36, respectively)
and VaD (1.61; 1.54-1.68; and 1.39; 1.28-1.50, respectively)
14 into MCI caused by AD (MCI-A), MCI caused
by VaD (MCI-VD), and MCI caused by ODs (MCI-O).
15 discriminated VaD from AD without
coexisting VaD with high accuracy.
16 ortem brain tissue in AD, vascular
dementia (
VaD) and controls.
17 20 AD, 20 control and 15 Vascular
dementia (
VaD) brains by real-time PCR (RT-PCR).
18 The clinical diagnosis of vascular
dementia (
VaD) is based on imaging criteria, and specific biochemi
19 lzheimer disease (AD) and vascular
dementia (
VaD) may be accelerated by hypercholesterolemia, the mec
20 heimer's disease (AD), 76 vascular
dementia (
VaD), and 811 control participants without dementia.
21 Alzheimer's disease (AD), vascular
dementia (
VaD), and all-cause dementia in persons with glaucoma co
22 , Alzheimer disease (AD), vascular
dementia (
VaD), and CIND by age.
23 Alzheimer's disease (AD), vascular
dementia (
VaD), and dementia caused by other diseases (ODs).
24 lzheimer disease (AD) and vascular
dementia (
VaD), is likely to increase as the population ages.
25 lzheimer disease (AD) and vascular
dementia (
VaD), is not well known.
26 Vascular
dementia (
VaD), the second-leading cause of dementia, is primarily
27 fusion is associated with vascular
dementia (
VaD).
28 disease (AD), and 35% of vascular
dementia (
VaD).
29 erebral hypoperfusion and vascular
dementia (
VaD).
30 eimer's disease (AD), and vascular
dementia (
VaD).
31 lzheimer disease (AD) and vascular
dementia (
VaD).
32 on developed AD, and about 637,000
developed VaD.
33 LCN2
discriminated VaD from AD without coexisting VaD with high accuracy.
34 tion for developing innovative therapies
for VaD.
35 -specific mouse VaD transcriptomes and
human VaD single-nucleus RNA sequencing (snRNA-seq) data plus
36 ents of the complex pathophysiology of
human VaD combined with transcriptomic and functional analyses
37 In VaD, KLK6 protein level was significantly increased in t
38 In VaD, the earliest and most consistent associations acros
39 erpine2-Lrp1 and CD39-A3AR, are disrupted
in VaD.
40 LCN2 was significantly elevated
in VaD compared to controls, Alzheimer's disease (AD), othe
41 rget for attenuating cognitive impairment
in VaD.
42 symptoms had more than a 3-fold increase
in VaD risk (3.51 [2.44-5.05]).
43 k factor for dementia with stroke,
including VaD and AD with CVD.
44 patients with dementia and stroke,
including VaD as currently defined, may include patients with AD.
45 f moderate to severe AD and mild to
moderate VaD, but it has not been studied specifically in mixed d
46 By integrating cell-type-specific
mouse VaD transcriptomes and human VaD single-nucleus RNA sequ
47 , 3.67; 95% CI, 2.04-6.60; P < .001) but
not VaD (HR, 2.03; 95% CI, 1.00-4.09; P = .05).
48 ical marker in the differential diagnosis
of VaD and neurodegenerative dementias.
49 arotid artery stenosis (BCAS) mouse model
of VaD to investigate its effect on the innate immune respo
50 nse relationship between BAS use and risk
of VaD (p-trend = 0.045) in males.Step 3: We assayed brain
51 a significant difference between the risk
of VaD in males compared to females (p = 0.040) and a signi
52 levels may be associated with higher risk
of VaD in males.
53 ologically associated with increased risk
of VaD.
54 ogen mRNA levels were unaltered in the AD
or VaD groups compared to the controls.
55 entia or neurology clinic diagnosis of AD
or VaD.
56 ymptom category and risk of dementia, AD,
or VaD.
57 The VaD neuroimaging phenotype consisted of total white matt
58 sue integrity and behavioral function in
the VaD model.
59 ed with dementia (5.5% with AD and 2.3%
with VaD).
60 y angle-closure glaucoma was associated
with VaD (1.26; 1.02-1.56) but not AD (0.98; 0.82-1.18).
61 stroke was 41% overall, 33% among those
with VaD, and 44% among those with AD with CVD.